Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Public ClinicalTrials.gov record NCT00068250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy such as methotrexate and temozolomide use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining methotrexate, temozolomide, and rituximab with radiation therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide when given together with methotrexate and rituximab followed by radiation therapy and to see how well they work in treating patients with primary central nervous system lymphoma.
Study identification
- NCT ID
- NCT00068250
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- rituximab Drug
- methotrexate Drug
- temozolomide 100 mg/m^2 Drug
- temozolomide 150 mg/m^2 Drug
- temozolomide 200 mg/m^2 Drug
- radiation therapy Radiation
- post-radiation therapy temozolomide Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2003 (Type not available)
- Primary completion
- Dec 2016 (Actual)
- Completion
- Dec 2016 (Actual)
- Last update posted
- Feb 7, 2018
2003 – 2016
United States locations
- U.S. sites
- 26
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baptist Cancer Institute - Jacksonville | Jacksonville | Florida | 32207 | — |
| Integrated Community Oncology Network at Southside Cancer Center | Jacksonville | Florida | 32207 | — |
| Baptist Medical Center South | Jacksonville | Florida | 32258 | — |
| Integrated Community Oncology Network | Jacksonville Beach | Florida | 32250 | — |
| Integrated Community Oncology Network - Orange Park | Orange Park | Florida | 32073 | — |
| Florida Cancer Center - Palatka | Palatka | Florida | 32177 | — |
| Flagler Cancer Center | Saint Augustine | Florida | 32086 | — |
| Borgess Medical Center | Kalamazoo | Michigan | 49001 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007-3731 | — |
| Bronson Methodist Hospital | Kalamazoo | Michigan | 49007 | — |
| CCOP - Kansas City | Kansas City | Missouri | 64131 | — |
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St Louis | Missouri | 63110 | — |
| CCOP - Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| John F. Kennedy Medical Center | Edison | New Jersey | 08818 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Providence Milwaukie Hospital | Milwaukie | Oregon | 97222 | — |
| Providence Cancer Center at Providence Portland Medical Center | Portland | Oregon | 97213-2967 | — |
| CCOP - Columbia River Oncology Program | Portland | Oregon | 97225 | — |
| Providence St. Vincent Medical Center | Portland | Oregon | 97225 | — |
| Kimmel Cancer Center at Thomas Jefferson University - Philadelphia | Philadelphia | Pennsylvania | 19107-5541 | — |
| Hollings Cancer Center at Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Jon and Karen Huntsman Cancer Center at Intermountain Medical Center | Murray | Utah | 84157 | — |
| Utah Valley Regional Medical Center - Provo | Provo | Utah | 84604 | — |
| Southwest Washington Medical Center Cancer Center | Vancouver | Washington | 98668 | — |
| Community Memorial Hospital Cancer Care Center | Menomonee Falls | Wisconsin | 53051 | — |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00068250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2018 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00068250 live on ClinicalTrials.gov.